A prospective study described the uropathogen frequencies and antimicrobial resistance rates of first UTI in 209 children who were diagnosed at the ED of a Belgian hospital.
A prospective study described the uropathogen frequencies and antimicrobial resistance rates of first UTI in 209 children (median age, 10 months) who were diagnosed at the ED of a Belgian hospital. The children were followed for 1 year.
Escherichia coli was by far the most common pathogen, accounting for 91% of UTIs. Fifty-eight percent of the E coli isolated were resistant to ampicillin, as were 36% to trimethoprim/sulfamethoxazole.
Other causative pathogens were Klebsiella pneumoniae, Proteus mirabilis, Enterobacter spp, and Streptococcus faecalis. Nitrofurantoin, temocillin, and amikacin were the most active agents against E coli, followed by cephalosporins of second and third generation, gentamicin, ciprofloxacin, and amoxicillin/clavulanic acid. Amikacin and temocillin also were the most active agents against K pneumoniae and P mirabilis.
Commentary
In this study, 25% of patients had urinary reflux on voiding cystourethrogram (VCUG), but 85% of the reflux was considered low grade (grades 1 to 3) and probably not worthy of prophylaxis or other interventions. In the 8 children with grade 4 or 5 reflux, 7 (88%) had an abnormal renal ultrasound. The overall sensitivity of ultrasound in detecting renal abnormalities, including high-grade but excluding low-grade reflux, was 97%. The number of patients with high-grade reflux in this study is small, so this article may not stand on its own, but along with other studies published and ongoing, it may allow us to move away from VCUG in routine evaluation of febrile UTIs. -Michael Burke, MD
CDC recommends nirsevimab be prioritized for highest-risk infants amid limited availability
October 26th 2023The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
Navigating a complex case of pediatric COVID-19 with immunomodulatory therapies
October 21st 2023Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.